These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 33283516)

  • 1. Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer.
    Martin MC; Zeng G; Yu J; Schiltz GE
    J Med Chem; 2020 Dec; 63(24):15344-15370. PubMed ID: 33283516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Embryonic Ectoderm Development (EED) as a Novel Target for Cancer Treatment.
    Cook N; Chen J; Zhou J; Wu D
    Curr Top Med Chem; 2021; 21(31):2771-2777. PubMed ID: 34544341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs.
    Zhao Y; Guan YY; Zhao F; Yu T; Zhang SJ; Zhang YZ; Duan YC; Zhou XL
    Eur J Med Chem; 2022 Mar; 231():114144. PubMed ID: 35093670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure of the PRC2 complex and application to drug discovery.
    Shi Y; Wang XX; Zhuang YW; Jiang Y; Melcher K; Xu HE
    Acta Pharmacol Sin; 2017 Jul; 38(7):963-976. PubMed ID: 28414199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allosteric Inactivation of Polycomb Repressive Complex 2 (PRC2) by Inhibiting Its Adapter Protein: Embryonic Ectodomain Development (EED).
    Yang CY; Wang S
    J Med Chem; 2017 Mar; 60(6):2212-2214. PubMed ID: 28256832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Noncanonical Function of Polycomb Repressive Complexes Promotes Human Cytomegalovirus Lytic DNA Replication and Serves as a Novel Cellular Target for Antiviral Intervention.
    Svrlanska A; Reichel A; Schilling EM; Scherer M; Stamminger T; Reuter N
    J Virol; 2019 May; 93(9):. PubMed ID: 30814291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
    Kong X; Chen L; Jiao L; Jiang X; Lian F; Lu J; Zhu K; Du D; Liu J; Ding H; Zhang N; Shen J; Zheng M; Chen K; Liu X; Jiang H; Luo C
    J Med Chem; 2014 Nov; 57(22):9512-21. PubMed ID: 25369470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance.
    Brooun A; Gajiwala KS; Deng YL; Liu W; Bolaños B; Bingham P; He YA; Diehl W; Grable N; Kung PP; Sutton S; Maegley KA; Yu X; Stewart AE
    Nat Commun; 2016 Apr; 7():11384. PubMed ID: 27122193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.
    Qi W; Zhao K; Gu J; Huang Y; Wang Y; Zhang H; Zhang M; Zhang J; Yu Z; Li L; Teng L; Chuai S; Zhang C; Zhao M; Chan H; Chen Z; Fang D; Fei Q; Feng L; Feng L; Gao Y; Ge H; Ge X; Li G; Lingel A; Lin Y; Liu Y; Luo F; Shi M; Wang L; Wang Z; Yu Y; Zeng J; Zeng C; Zhang L; Zhang Q; Zhou S; Oyang C; Atadja P; Li E
    Nat Chem Biol; 2017 Apr; 13(4):381-388. PubMed ID: 28135235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and Assessments of Novel and Potent Small-Molecule Inhibitors of EED-EZH2 Interaction of Polycomb Repressive Complex 2 by Computational Methods and Biological Evaluations.
    Zhu K; Du D; Yang R; Tao H; Zhang H
    Chem Pharm Bull (Tokyo); 2020 Jan; 68(1):58-63. PubMed ID: 31685780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of catalytic and non-catalytic activity inhibitors against PRC2-EZH2 complex through multiple high-throughput screening campaigns.
    Zhou Y; Du DH; Wang J; Cai XQ; Deng AX; Nosjean O; Boutin JA; Renard P; Yang DH; Luo C; Wang MW
    Chem Biol Drug Des; 2020 Oct; 96(4):1024-1051. PubMed ID: 32394628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
    Xu B; Konze KD; Jin J; Wang GG
    Exp Hematol; 2015 Aug; 43(8):698-712. PubMed ID: 26027790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polycomb Repressive Complex 2 in Oncology.
    Guo Y; Yu Y; Wang GG
    Cancer Treat Res; 2023; 190():273-320. PubMed ID: 38113005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct Stimulatory Mechanisms Regulate the Catalytic Activity of Polycomb Repressive Complex 2.
    Lee CH; Holder M; Grau D; Saldaña-Meyer R; Yu JR; Ganai RA; Zhang J; Wang M; LeRoy G; Dobenecker MW; Reinberg D; Armache KJ
    Mol Cell; 2018 May; 70(3):435-448.e5. PubMed ID: 29681498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in genes encoding polycomb repressive complex 2 subunits cause Weaver syndrome.
    Imagawa E; Higashimoto K; Sakai Y; Numakura C; Okamoto N; Matsunaga S; Ryo A; Sato Y; Sanefuji M; Ihara K; Takada Y; Nishimura G; Saitsu H; Mizuguchi T; Miyatake S; Nakashima M; Miyake N; Soejima H; Matsumoto N
    Hum Mutat; 2017 Jun; 38(6):637-648. PubMed ID: 28229514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic Protein Interactions of the Polycomb Repressive Complex 2 during Differentiation of Pluripotent Cells.
    Oliviero G; Brien GL; Waston A; Streubel G; Jerman E; Andrews D; Doyle B; Munawar N; Wynne K; Crean J; Bracken AP; Cagney G
    Mol Cell Proteomics; 2016 Nov; 15(11):3450-3460. PubMed ID: 27634302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.
    Wassef M; Luscan A; Aflaki S; Zielinski D; Jansen PWTC; Baymaz HI; Battistella A; Kersouani C; Servant N; Wallace MR; Romero P; Kosmider O; Just PA; Hivelin M; Jacques S; Vincent-Salomon A; Vermeulen M; Vidaud M; Pasmant E; Margueron R
    Proc Natl Acad Sci U S A; 2019 Mar; 116(13):6075-6080. PubMed ID: 30867289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting histone methyltransferase EZH2 as cancer treatment.
    Kondo Y
    J Biochem; 2014 Nov; 156(5):249-57. PubMed ID: 25179367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer.
    Kim W; Bird GH; Neff T; Guo G; Kerenyi MA; Walensky LD; Orkin SH
    Nat Chem Biol; 2013 Oct; 9(10):643-50. PubMed ID: 23974116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of polycomb repressive complex 2 key components EZH2/SUZ12/EED as an unfavorable prognostic marker in cholangiocarcinoma.
    Wasenang W; Puapairoj A; Settasatian C; Proungvitaya S; Limpaiboon T
    Pathol Res Pract; 2019 Jul; 215(7):152451. PubMed ID: 31126817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.